Rocket Pharmaceuticals, Inc.
RCKTNASDAQHealthcare● Active
$2.70
$-0.05(-1.82%)
Market Cap$294822582
P/E Ratio—
52W High$5.45
52W Low$2.4
Rocket Pharmaceuticals, Inc. (RCKT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RCKT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.42
Est. -$0.41 · -2.4%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS
RCKT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $1.04 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.41 | -$0.42 | -2.4% | — | $0.00B | — |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.42 | -$0.38 | +9.5% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.48 | -$0.45 | +6.3% | — | $0.00B | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.57 | -$0.59 | -3.5% | — | $0.00B | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.59 | -$0.56 | +5.1% | — | $0.00B | — |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.68 | -$0.62 | +8.8% | — | $0.00B | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.78 | -$0.71 | +9.0% | — | $0.00B | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$1.04
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.42
EPS Est.
-$0.41
EPS Surpr.
-2.4%
Revenue
—
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.38
EPS Est.
-$0.42
EPS Surpr.
+9.5%
Revenue
—
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.45
EPS Est.
-$0.48
EPS Surpr.
+6.3%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.59
EPS Est.
-$0.57
EPS Surpr.
-3.5%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.56
EPS Est.
-$0.59
EPS Surpr.
+5.1%
Revenue
—
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.62
EPS Est.
-$0.68
EPS Surpr.
+8.8%
Revenue
—
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.71
EPS Est.
-$0.78
EPS Surpr.
+9.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Q3 FY2027 | $-0.34 | $-0.34 | $-0.34 | 1 |
| Q2 FY2027 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Q1 FY2027 | $-0.42 | $-0.42 | $-0.42 | 1 |
| Q4 FY2026 | $-0.42 | $-0.42 | $-0.42 | 1 |
| Q3 FY2026 | $-0.56 | $-0.43 | $-0.33 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -2.4% | $3.86 | $3.67 | -4.92% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +9.5% | $4.33 | $4.53 | +4.62% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +6.3% | $3.32 | $3.23 | -2.71% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -3.5% | $3.02 | $3.09 | +2.32% |
| ▲ Q2 FY2025 | May 8, 2025 | +5.1% | $6.70 | $7.04 | +5.07% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +8.8% | $9.52 | $9.40 | -1.26% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +9.0% | $17.58 | $17.25 | -1.88% |
| ▲ Q3 FY2024 | Aug 5, 2024 | +0.0% | $20.88 | $19.96 | -4.41% |
Q2 FY2026-4.92%
Report Date
May 7, 2026
EPS Beat/Miss
-2.4%
Price Before
$3.86
Price After
$3.67
Q1 FY2026+4.62%
Report Date
Feb 26, 2026
EPS Beat/Miss
+9.5%
Price Before
$4.33
Price After
$4.53
Q4 FY2025-2.71%
Report Date
Nov 6, 2025
EPS Beat/Miss
+6.3%
Price Before
$3.32
Price After
$3.23
Q3 FY2025+2.32%
Report Date
Aug 7, 2025
EPS Beat/Miss
-3.5%
Price Before
$3.02
Price After
$3.09
Q2 FY2025+5.07%
Report Date
May 8, 2025
EPS Beat/Miss
+5.1%
Price Before
$6.70
Price After
$7.04
Q1 FY2025-1.26%
Report Date
Feb 27, 2025
EPS Beat/Miss
+8.8%
Price Before
$9.52
Price After
$9.40
Q4 FY2024-1.88%
Report Date
Nov 7, 2024
EPS Beat/Miss
+9.0%
Price Before
$17.58
Price After
$17.25
Q3 FY2024-4.41%
Report Date
Aug 5, 2024
EPS Beat/Miss
+0.0%
Price Before
$20.88
Price After
$19.96
Avg Beat Reaction-0.09%
Avg Miss Reaction-1.30%
Beat Rate6 / 8 quarters
Largest Move+5.07% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RCKT ends December
Rocket Pharmaceuticals, Inc. (RCKT) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.42 — missing the analyst consensus of $-0.41 by -2.4%. The next RCKT earnings date is expected around September 1, 2026.
Each quarter, investors track RCKT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RCKT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RCKT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RCKT earnings · 5 questionsRocket Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. RCKT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RCKT historically reports after market close (AMC).
RCKT earnings datewhen is RCKT earningsRCKT next earnings datewhen does RCKT report earningsRCKT earnings calendar
▸ Source: FMP · Rocket Pharmaceuticals, Inc. SEC filings · US GAAP · Rocket Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026